Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

weeks," said Prof. Landmesser. "The data will be presented at a conference later this year."

About the Genous Technology

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients that are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... New Practice Leaders Appointed, RESEARCH TRIANGLE ... today announced the appointment of three new ... part of its expanding Quintiles,Consulting business, which ... strategic guidance to maximize potential and minimize,risk ...
... Across All Product Lines ... - Special ... 22 Edwards Lifesciences,Corporation (NYSE: EW ), a world leader ... income for the,quarter ended March 31, 2008 of $18.2 million, or ...
... April 22 Rochester,Medical Corporation (Nasdaq: ROCM ) ... April 29, 2008. The Company will then,hold a quarterly ... begin at 4:00 p.m. central daylight time (5:00 p.m. ... Thomson/CCBN and can be accessed at,Rochester Medical,s website at ...
Cached Biology Technology:Quintiles Consulting Business Expands 2Quintiles Consulting Business Expands 3Quintiles Consulting Business Expands 4Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 2Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 3Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 4Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 5Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 6Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 7Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 8Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 9Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 10Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 11Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 12Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 13Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 14Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008 2
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... to have a bad reputation. They sleep all day, party at ... study by University of Calgary researchers has confirmed that bats are ... that bats have high rates of rabies is not true," says ... the lead author of a paper published in the Journal ...
... Research by the University of Exeter has revealed that ants ... result of their activity as ,ecosystem engineers, and predators. ... , found that ants have two distinct effects on their ... building activity and by collecting food they affect the level ...
... Scripps Research Institute scientists have converted adult skin ... to first go through the laborious process of generating ... lead to new treatments for a range of diseases ... heart disease, Parkinson,s, and Alzheimer,s disease. The work ...
Cached Biology News:Researchers bust bat rabies stereotype 2Ants' ecosystem role is 'key' 2Scripps Research scientists convert skin cells to beating heart cells 2Scripps Research scientists convert skin cells to beating heart cells 3
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
...
Biology Products: